A new survey has revealed that over 79% of Canadians support psychedelic-assisted therapy for existential distress at the end of life.
A groundbreaking observational study is set to investigate the real-world efficacy of MDMA-assisted therapy through Health Canada’s Special Access Programme (SAP).
A new report has been released by Canada’s Senate Subcommittee on Veterans Affairs – ‘The Time Is Now: Granting Equitable Access to Psychedelic Assisted Therapies’ –...
Canada’s non-profit advocacy organisation TheraPsil has announced the launch of its MDMA-assisted psychotherapy training programme.
In a groundbreaking move for Canada’s regulatory developments around psychedelics, Alberta has announced it will be introducing quality standards into its Mental Health Services Protection Act...
Awakn Life Sciences has signed its first licensing partnership agreement in Canada with Ontario-based Wellbeings Pain Management and Dependency Clinic, which is focused on multi-disciplinary, evidence-based,...
In a move that aims to provide patients in Canada with the “life-changing opportunity” to receive psilocybin-assisted psychotherapy, TheraPsil and Drug Science are collaborating to launch...
Health Canada has granted approval to Numinus’ application to complete psychedelic-assisted therapy using psilocybin to treat an applicant with treatment-resistant depression.
The Canadian Government has amended regulation in order to allow patients to access psychedelic medicines such as psilocybin and MDMA.
